Sep 7, 2026 —
Rznomics, a South Korea-based developer of RNA-based gene therapies, has reported a breakthrough in the high-efficiency production of circular RNA (circRNA), published in Nucleic Acids Research on September 4, 2026.
The study reports that optimized target-site selection and P1 engineering improved self-circularization efficiency by up to approximately sevenfold versus the original STS design. For a roughly 7.8-kilonucleotide Factor VIII RNA, the optimized method achieved about twice the circularization efficiency of the widely used permuted intron-exon method.
Improved circRNA production could broaden the range of RNA-based medicines that can be manufactured at scale.
